Margherita Fabbri, MD, PhD, University of Toulouse, Toulouse, France, gives an overview of ongoing clinical trials in atypical parkinsonism. There are a few positive Phase II trials evaluating novel therapies for dementia with Lewy bodies and multiple system atrophy, but overall the clinical trials in atypical parkinsonisms haven’t delivered positive results. Nevertheless, the role of non-pharmacological treatments and the development of novel targets are two emerging topics in the field of atypical parkinsonism that could influence future clinical trials. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.